Latest Breaking News On - Spot in the bio boom - Page 1 : comparemela.com

PacBio’s HiFi and SMRT sequencing technology continues to fuel growth. PACB believes itself to be on track to hit its full-year revenue guidance of ~$160-$170M. See why I rate PACB as a buy.

United statesOxford nanoporeCathie woodPacific biosciencesAsuragen amplideDanaher corpCompounding healthcareBio boomBerry genomicsGenomics englandSpot in the bio boomBio boom portfolioPacbio annual revenue estimatesSeeking alphaDaily keltner channelMonthly keltner channel